C.R. Bard, Inc. (Bard) has reported net sales of $637 million for the third quarter of 2009, up 3%, compared with the net sales of $616.8 million in the year ago quarter. It has also reported a net income of $130 million for the third quarter of 2009, compared with the net income of $112.1 million in the year ago quarter.
For the third quarter 2009, net sales in the U.S. were $442.6 million and net sales outside the U.S. were $194.4 million, an increase of 6% and a decrease of 1%, respectively, over the prior-year period. Excluding the impact of foreign exchange, third quarter 2009 net sales outside the U.S. increased 7% over the prior-year period.
For the third quarter 2009, net income attributable to common shareholders was $129.5 million and diluted earnings per share available to common shareholders were $1.31, an increase of 16% and 21%, respectively, as compared to third quarter 2008 results. Adjusting for items that affect comparability between periods as detailed in the tables below, third quarter 2009 net income attributable to common shareholders and diluted earnings per share available to common shareholders increased 15% and 20%, respectively, as compared to third quarter 2008 results.
Timothy M. Ring, chairman and chief executive officer, commented, “Bard delivered another quarter of strong EPS performance while funding a record level of organic investment in R&D. We remain focused on the future through the development and acquisition of products that are differentiated by their clinical and economic benefits. We believe that superior technology is key to improving the lives of patients and sustaining a product leadership position in the market.”